The stock market overcame some mixed economic data on Friday after the Supreme Court overruled International Emergency Economic Powers Act to enact tariffs. The Dow Jones Industrial Average rose 231 ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. President Donald Trump is seeking to allay fears ...
Hosted on MSN
WhiteFiber stock pops 25% premarket on $865M Nscale data center deal – retail traders price in long-term AI revenue
・WhiteFiber will deliver 40 megawatts of critical IT load at the NC-1 data center campus in Madison, North Carolina, in two 20-megawatt phases. ・WhiteFiber said it has invested roughly $150 million in ...
What's the best AI data center infrastructure stock right now for investors? Seeking Alpha analysts Ricardo Fernandez and Petri Dish Reports weigh in. Ricardo Fernandez: In my view, the AI data center ...
Over the past six months, investors have weathered some major swings in the U.S. equity market. The Big Tech stocks, which had done much of the heavy lifting since the start of the current bull market ...
Marvell enters 2026 with momentum in its data center business. Marvell forecasts revenue to hit $11 billion in fiscal 2027, representing over 30% growth. The stock trades at 24 times this year's ...
The S&P 500 is down nearly 9 percent from a January high. The weekly losing streak is its worst in roughly four years. Orange-shaded bars indicate weekly losses from end of previous week. Source: LSEG ...
Google is providing construction financing for a massive Texas data center currently under lease to Anthropic Nexus Data Centers’ project exceeds $5 billion, with construction loans nearing completion ...
While participants on a lower dose of Wave Life Sciences’ RNA therapy lost 5.3% total fat at the six-month mark, those receiving the higher dose saw a less than 1% drop at three months. Wave Life ...
Cipher Digital rose sharply Wednesday after the data-center operator announced a new 15-year lease with a hyperscaler at one of its facilities—yet another sign of robust demand for ...
Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” The once-daily oral small molecule APOL1 inhibitor, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results